Value202020212022202320242025TTMSelling/general/admin expenses18.37 M13.9 M10.21 M9.89 M9.47 M70.13 M29.24 MResearch & development0————41.33 M—Operating income61.32 M80.45 M9.42 M-25.44 M-20.54 M-110.51 M-27.83 MNon-Operating Income, Total————5.58 M-140.13 M—Interest expense, net of interest capitalized—————3.87 M—Non-Operating Income, excl. Interest Expenses————-2.92 M-144.04 M—Unusual income/expense————8.5 M43 K—Pretax income-103.86 M-96.92 M-79.97 M-96.36 M-128.03 M-250.64 M-273.06 MEquity in earnings-1.18 M-3 000862 K00——Taxes-82 K-160 K-189 K-458 K-1.79 M3 0003 000Non-controlling/minority interest00—————After tax other income/expense-226 K-24 K-106 K-2 00000—Net income before discontinued operations-103.77 M-96.77 M-79.78 M-95.9 M-126.23 M-250.64 M-204.42 MDiscontinued operations-66.75 M4.6 M108.09 M000—Net income-170.52 M-92.17 M28.32 M-95.9 M-126.23 M-250.64 M-204.42 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders-170.52 M-92.17 M28.32 M-95.9 M-126.23 M-429.64 M-383.42 MBasic earnings per share (Basic EPS)—-0.470.14-0.39-0.47-1.37-1.21Diluted earnings per share (Diluted EPS)—-0.470.14-0.39-0.47-1.37-1.21Average basic shares outstanding—197.76 M200.36 M244.54 M267.73 M312.98 M—Diluted shares outstanding—197.76 M200.36 M244.54 M267.73 M312.98 M—EBITDA87.72 M94.51 M21.03 M-18.77 M-16.01 M-107.31 M—EBIT61.32 M80.45 M9.42 M-25.44 M-20.54 M-110.51 M—Cost of revenue———————Other cost of goods sold———————Depreciation & amortization (cash flow)17.52 M13.76 M10.77 M6.67 M4.53 M3.2 M3.67 M
Precigen, Inc. - Common Stock
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.